Viral Vaccines Market Size, Share, Forecast, & Trends Analysis by Form Type Virus, Approach, Indication, Application, Packaging

Description

List of Tables

Viral Vaccines Market Size, Share, Forecast, & Trends Analysis by Form (Liquid, Lyophilized) Type (Live Attenuated, mRNA, Inactivated) Virus (Adenovirus, Retrovirus, Plasmid DNA, AAV), Approach, Indication, Application, Packaging-Global Forecast to 2031

The viral vaccines market is projected to reach $47.01 billion by 2031, at a CAGR of 1.9% from 2024 to 2031.

Following a comprehensive primary and secondary study and an in-depth analysis of the market scenario, this report provides the key drivers, constraints, challenges, and opportunities of the industry. This market is driven by the increasing government focus on immunization programs, technological advancements in vaccine administration, and the use of inactivated vaccines in surgeries or treatment.

Furthermore, the growing focus on therapeutic vaccines, increasing use of adjuvants in vaccines, growth prospects in emerging markets, and development of highly stable and energy-efficient ultra-low temperature freezers provide a significant growth opportunity for this market. However, the high costs involved in vaccine development and long timelines of vaccine manufacturing may restrain the growth of this market. Additionally, product recalls and inadequate access to vaccines pose a major challenge for the players operating in this market.

Among forms, in 2024, the liquid vaccines segment is expected to account for the largest share of above 90.3% of the viral vaccines market. The large market share of this segment is attributed to factors such as ease of administration, reduced risk of errors, reduced wastage, improved patient experience, low production costs, and better stability. Bharat Biotech Ltd. (India), a vaccines and bio-therapeutics manufacturer, has a live attenuated rotavirus vaccine included in its product portfolio that is a liquid frozen vaccine containing live rotavirus 116E strain and is used for the prevention of rotavirus gastroenteritis.

Among vaccine types, in 2024, the subunit & conjugate vaccines segment is expected to account for the largest share of the viral vaccines market. The large market share of this segment is attributed to factors such as subunit & conjugate vaccines' low risk of immunogenicity and long-term immunity. Moreover, certain modifications have been made to the physio-chemical properties of carrier proteins to achieve optimum antigenic representation, cellular trafficking reduction, and uniform vaccine distribution. Therefore, with ongoing advancements, the adoption of subunit & conjugate vaccines is expected to increase.

Among virus types, in 2024, the adenovirus segment is expected to account for the largest share of the viral vaccines market. This segment's large market share is attributed to factors such as better stability compared to other viruses, efficient gene delivery, strong immune response, replication-incompetent viruses, and high scalability. Additionally, adenoviruses have been extensively studied and used in multiple vaccine trials, providing knowledge and experience in their development and optimization for vaccine purposes.

Among approaches, in 2024, the preventive vaccines segment is expected to account for the larger share of the viral vaccines market. The large market share of this segment is attributed to factors such as the increasing prevalence of chronic and infectious diseases, rising awareness for immunization in public, growing immunization programs, and induction of herd immunity due to the use of these preventive viruses. For instance, in February 2024, under the Viksit Bharat by 2047 campaign, the Union Minister for Finance & Corporate Affairs of India proposed a vaccination program to prevent cervical cancer in girls of age group 9 to 14.

Among indications, in 2024, the infectious diseases segment is expected to account for the largest share of the market. The large share of the segment is attributed to factors such as effectiveness in preventing infectious diseases, faster spread of infectious diseases, and rising risk of pandemics. Viral vaccines for infectious diseases have been used earlier for eradication or near-elimination of diseases such as smallpox and polio in many parts of the world and have significantly reduced the burden of other diseases such as measles, mumps, and rubella.

Among applications, in 2024, the antisense therapy segment is expected to account for the largest share of the market. Antisense therapy is a technique that is used to tackle conditions such as neurodegenerative disorders, viral infections, and cancers using short DNA-like molecules called antisense oligonucleotides. The large share of the segment is attributed to factors such as the growing prevalence of infectious diseases, technological advancements in the use of viral vectors, and increasing healthcare expenditure.

An in-depth analysis of the geographical scenario of the viral vaccines market provides detailed qualitative and quantitative insights for the five major geographies (North America, Europe, Asia-Pacific, the Middle East & Africa, and Latin America) along with the coverage of major countries in each region.

In 2024, North America is expected to account for the largest share of above 44.0% of the viral vaccines market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The large market share of this segment is primarily due to the presence of leading manufacturers, large R&D investments, support from government and regulatory authorities, a rise in the number of infections, the presence of healthcare professionals to administer vaccines, and growing immunization programs for vaccination.

The key players operating in the viral vaccines market are Pfizer, Inc. (U.S.), AstraZeneca plc (U.K.), GlaxoSmithKline plc (U.K.), Sanofi S.A. (Italy), CSL Ltd. (Australia), Mitsubishi Tanabe Pharma Corporation (Japan), Merck & Co., Inc. (U.S.), Moderna, Inc. (U.S.), Johnson & Johnson Services, Inc. (U.S.), Dynavax Technologies Corporation (U.S.), Serum Institute of India Pvt. Ltd (India), Emergent BioSolutions, Inc. (U.S.), Bharat Biotech International Limited (BBIL) (India), and Valneva SE (France).

Scope of the Report:

Viral Vaccines Market-by Form

Liquid Vaccines
Lyophilized Vaccines

Viral Vaccines Market-by Vaccine Type

Subunit & Conjugate Vaccines
Live-attenuated Vaccines
Inactivated Vaccines
mRNA Vaccines
Viral Vector Vaccines
Toxoid Vaccines
Combination Vaccines

Viral Vaccines Market-by Virus Type

Adenovirus
Retrovirus
Plasmid DNA
Adeno-associated Virus (AAV)
Lentivirus
Other Virus Types

(Other virus types include norovirus and DNA viruses)

Viral Vaccines Market-by Route of Administration

Intramuscular (IM)
Subcutaneous (SC)
Oral
Other Routes of Administration

(Other virus types include norovirus and DNA viruses)

Viral Vaccines Market-by Approach

Preventive Vaccines
Therapeutic Vaccines

Viral Vaccines Market-by Indication

Infectious Diseases
Cancer
Genetic Disorders
Other Indications

(Other indications include varicella, herpes zoster vaccines, chlorella, severe acute respiratory syndrome, and rabies diseases)

Viral Vaccines Market-by Application

Antisense Therapy
Gene Therapy
Cell Therapy
Vaccinology

Viral Vaccines Market-by Packaging

Vials
Prefilled Syringes

Viral Vaccines Market-by Geography

North America
- U.S.
- Canada
Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Switzerland
- Ireland
- Denmark
- Belgium
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa

Product Code: MRHC - 1041237

1. Introduction

1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency and Limitations
1.4. Key Stakeholders

2. Research Methodology

2.1. Research Approach
2.2. Process of Data Collection and Validation
- 2.2.1. Secondary Research
- 2.2.2. Primary Research/Interviews with Key Opinion Leaders from the Industry
2.3. Market Sizing and Forecast
- 2.3.1. Market Size Estimation Approach
- 2.3.2. Growth Forecast Approach
- 2.3.3. Market Share Analysis
2.4. Assumption for the Study

3. Executive Summary

4. Market Insights

4.1. Overview
4.2. Drivers
- 4.2.1. Increasing Government Focus on Immunization Programs
- 4.2.2. Technological Advancements in Vaccine Administration
- 4.2.3. Use of Inactivated Vaccines in Surgeries or Treatment
4.3. Restraints
- 4.3.1. High Costs Involved in Vaccine Development
- 4.3.2. Long Timelines of Vaccine Manufacturing
4.4. Opportunities
- 4.4.1. Growing Focus on Therapeutic Vaccines
- 4.4.2. Increasing Use of Adjuvants in Vaccines
- 4.4.3. Growth Prospects in Emerging Markets
- 4.4.4. Development of Highly Stable and Energy-efficient Ultra-low Temperature Freezers
4.5. Challenges
- 4.5.1. Product Recalls
- 4.5.2. Inadequate Access to Vaccines
4.6. Technology Trends/Market Trends
- 4.6.1. Increasing Preference for Personalized Treatments
- 4.6.2. Media and Public Awareness Regarding Immunization
4.7. Regulatory Scenario
4.8. Pricing Analysis
4.9. Parent Market Analysis
4.10. Porter's Five Forces Analysis

5. Viral Vaccines Market-by Form

5.1. Overview
5.2. Liquid Vaccines
5.3. Lyophilized Vaccines

6. Viral Vaccines Market-by Vaccine Type

6.1. Overview
6.2. Subunit & Conjugate Vaccines
6.3. Live-attenuated Vaccines
6.4. Inactivated Vaccines
6.5. mRNA Vaccines
6.6. Viral Vector Vaccines
6.7. Toxoid Vaccines
6.8. Combination Vaccines

7. Viral Vaccines Market-by Virus Type

7.1. Overview
7.2. Adenovirus
7.3. Retrovirus
7.4. Plasmid DNA
7.5. Adeno-associated Virus (AAV)
7.6. Lentivirus
7.7. Other Virus Types

8. Viral Vaccines Market-by Route of Administration

8.1. Overview
8.2. Intramuscular (IM)
8.3. Subcutaneous (SC)
8.4. Oral
8.5. Other Routes of Administration

9. Viral Vaccines Market-by Approach

9.1. Overview
9.2. Preventive
9.3. Therapeutic

10. Viral Vaccines Market-by Indication

10.1. Overview
10.2. Cancer
10.3. Genetic Disorders
10.4. Infectious Diseases
10.5. Other Indications

11. Viral Vaccines Market-by Application

11.1. Overview
11.2. Antisense Therapy
11.3. Gene Therapy
11.4. Cell Therapy
11.5. Vaccinology

12. Viral Vaccines Market-by Packaging

12.1. Vials
12.2. Prefilled Syringes

13. Viral Vaccines Market-by Geography

13.1. Overview
13.2. North America
- 13.2.1. U.S.
- 13.2.2. Canada
13.3. Europe
- 13.3.1. Germany
- 13.3.2. France
- 13.3.3. U.K.
- 13.3.4. Italy
- 13.3.5. Spain
- 13.3.6. Switzerland
- 13.3.7. Ireland
- 13.3.8. Denmark
- 13.3.9. Belgium
- 13.3.10. Rest of Europe
13.4. Asia-Pacific
- 13.4.1. Japan
- 13.4.2. China
- 13.4.3. India
- 13.4.4. South Korea
- 13.4.5. Rest of Asia Pacific
13.5. Latin America
- 13.5.1. Brazil
- 13.5.2. Mexico
- 13.5.3. Rest of Latin America
13.6. Middle East & Africa

14. Competitive Analysis

14.1. Overview
14.2. Key Growth Strategies
14.3. Competitive Benchmarking
14.4. Competitive Dashboard
- 14.4.1. Market Leaders
- 14.4.2. Market Differentiators
- 14.4.3. Vanguards
- 14.4.4. Emerging Companies
14.5. Market Share Analysis/ Market Ranking, by Key Players (2023)

15. Company Profiles (Company Overview, Financial Overview, Product Portfolio, Strategic Developments, and SWOT Analysis*)

15.1. Pfizer, Inc.
15.2. AstraZeneca plc
15.3. GlaxoSmithKline plc
15.4. Sanofi S.A.
15.5. CSL Ltd.
15.6. Mitsubishi Tanabe Pharma Corporation
15.7. Merck & Co., Inc.
15.8. Moderna, Inc.
15.9. Johnson & Johnson Services, Inc.
15.10. Dynavax Technologies Corporation
15.11. Serum Institute of India Pvt. Ltd
15.12. Emergent BioSolutions, Inc.
15.13. Bharat Biotech International Limited (BBIL)
15.14. Valneva SE

(Note: SWOT analysis will be provided for the top 5 players only)

16. Appendix

16.1. Available Customization
16.2. Related Reports